Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6623394 | 0.86 | SLC13A5 (0.33) | — | |
| SCHEMBL5862668 | 0.79 | SLC13A5 (0.32) | STING1 | |
| SCHEMBL3141578 | 0.69 | SLC13A5 (0.33) | STING1 | |
| SCHEMBL614127 | 0.65 | PDE4A (0.31) | — | |
| SCHEMBL5859815 | 0.64 | SLC13A5 (0.34) | — | |
| SCHEMBL2798693 | 0.64 | SLC13A5 (0.42) | — | |
| SCHEMBL3141597 | 0.62 | JAK2 (0.33) | STING1 | |
| SCHEMBL6787926 | 0.58 | KDM4E (0.32) | — | |
| SCHEMBL2210649 | 0.58 | HMGCR (0.35) | — | |
| SCHEMBL6764302 | 0.58 | HMGCR (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120136153-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-05-31 | — | — | US | disclosed |
| US-7982041-B2 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090198061-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-08-06 | — | — | US | disclosed |
| US-7538220-B2 | Intermediates in the preparation of homocamptothecin analogs | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2009-05-26 | — | — | US | disclosed |
| EP-1173180-B1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | UNIV PITTSBURGH (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20080027224-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-01-31 | — | — | US | disclosed |
| US-7220860-B2 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF PITTSBURGH (US) | 2007-05-22 | — | — | US | disclosed |
| US-20050014775-A1 | Camptothecin analogs and methods of preparation thereof | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2005-01-20 | — | — | US | disclosed |
| US-6809103-B2 | E-RING EXPANDED CAMPTOTHECIN DERIVATIVES | UNIVERSITY OF PITTSBURGH | 2004-10-26 | — | — | US | disclosed |
| US-20030088101-A1 | E-ring expanded camptothecin derivatives | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2003-05-08 | — | — | US | disclosed |
| US-6410731-B2 | ENHANCED LIPOPHILICITY, BIOAVAILABILITY; MADE VIA A CASCADE RADICAL 4+1 ANNULATION INCLUDING REACTING A PRECURSOR WITH AN ARYLISONITRILE | UNIVERSITY OF PITTSBURGH | 2002-06-25 | — | — | US | disclosed |
| US-20010003779-A1 | Camptothecin analogs and methods of preparation thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2001-06-14 | — | — | US | disclosed |
| US-6207832-B1 | ANTICANCER AGENTS | UNIVERSITY OF PITTSBURGH | 2001-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003779-A1 | Camptothecin analogs and methods of preparation thereof | TOP1, CBR1, TOP2B | STING1 754/4885 |
| US-20030088101-A1 | E-ring expanded camptothecin derivatives | REL, TOP1, RRM1 | STING1 1503/4885 |
| US-20090198061-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | TOP2A, TOP2B, ERCC4 | STING1 1235/4885 |
| US-20050014775-A1 | Camptothecin analogs and methods of preparation thereof | NR0B1, NR5A1, REL | STING1 2927/4885 |
| US-20120136153-A1 | CAMPTOTHECIN ANALOGS AND METHODS OF PREPARATION THEREOF | TOP2A, TOP2B, ERCC4 | STING1 1235/4885 |
| US-20080027224-A1 | Camptothecin analogs and methods of preparation thereof | NR0B1, HCCS, NR0B2 | STING1 1912/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.